It seems quite amusing to see folks crying over something that every single long shareholder should have known and expected all along, even 5 years ago or 5 months ago!
Do folks actually put money they can not afford to lose in these speculative investment stocks?
Do people actually expect ACTC to develop a new medical technology and get it approved by the FDA in 5 or 10 years?
Do people really think ACTC can do all of this on 50 or 100 million dollars, when the average drug development takes 1 to 4 billion?
Got to laugh at the unrealistic expectations!!!
IMO, if they are able figure out what it takes to get the success rate of the first two patients of 100 percent success rate. If they can figure out why the one recent case is so successful, then if will not take less than 10 million to run a phase 3 registration trial. For example, high ambient temperature may be a way to increase cell growth and success rates, as the first two patients were injected during the summer (7/12/11) in LA, Calif, while little is heard from those injected not in the summer, and injected in colder cities.
DNDN's phase 3 trial needed about 500 patients, and DNDN's success rate was about 30 percent if recalled correctly to get the p-value low enough for FDA approval.
At about $15,000 cost per trial patient, 500 patient trial may cost around 7 and a half million dollars trial cost.
If the success rate can be increased to above 60 percent, less patients may be needed for the eye trial. If the trial can be done with 330 patients at 15K each, the cost may be around 5 million.